Ipsen to Showcase New PBC Findings with IQIRVO from ELATIVE Study

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Nov 07 2025

0mins

Presentation of New Data: Ipsen will present new data on IQIRVO for Primary Biliary Cholangitis (PBC) from the ELATIVE trial at The Liver Meeting 2025, highlighting sustained improvements in biomarkers and symptoms after over three years of follow-up in 115 patients.
Clinical Efficacy: The interim results show that 72% of patients maintained a biochemical response, with a significant reduction in alkaline phosphatase levels and sustained improvements in fatigue and pruritus symptoms, indicating potential for slowing disease progression.
Safety Profile: The long-term safety profile of IQIRVO remains well-characterized with no new safety signals reported, supporting its use in treating PBC.
Fatigue Management: The analysis of fatigue-associated proteins suggests that IQIRVO may effectively address fatigue in PBC patients, with around 50% of participants reporting significant reductions in fatigue severity compared to placebo.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.